Barclays PLC Schrodinger, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Schrodinger, Inc. stock. As of the latest transaction made, Barclays PLC holds 107,554 shares of SDGR stock, worth $2.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

107,554

Previous 107,554 -0.0%

Holding current value

$2.13 Million

Previous $2 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$18.05 - $24.02 $1.57 Million - $2.09 Million	86,933 Added 421.58%	107,554 $2 Million
Q2 2024 Aug 14, 2024	SELL	$18.65 - $28.5 $562,297 - $859,275	-30,150 Reduced 59.38%	20,621 $399,000
Q1 2024 May 15, 2024	SELL	$24.74 - $35.13 $902,737 - $1.28 Million	-36,489 Reduced 41.82%	50,771 $1.37 Million
Q4 2023 Feb 15, 2024	BUY	$21.62 - $37.21 $1.23 Million - $2.11 Million	56,689 Added 185.43%	87,260 $3.12 Million
Q3 2023 Nov 07, 2023	SELL	$27.34 - $55.37 $276,380 - $559,735	-10,109 Reduced 24.85%	30,571 $864,000
Q2 2023 Aug 03, 2023	BUY	$26.1 - $49.92 $24,325 - $46,525	932 Added 2.34%	40,680 $2.03 Million
Q1 2023 May 04, 2023	BUY	$18.09 - $27.61 $231,823 - $353,822	12,815 Added 47.58%	39,748 $1.05 Million
Q4 2022 Feb 13, 2023	BUY	$16.24 - $26.38 $105,007 - $170,573	6,466 Added 31.59%	26,933 $504,000
Q3 2022 Nov 03, 2022	BUY	$23.95 - $34.71 $38,439 - $55,709	1,605 Added 8.51%	20,467 $511,000
Q2 2022 Aug 12, 2022	SELL	$21.39 - $35.9 $224,552 - $376,878	-10,498 Reduced 35.76%	18,862 $499,000
Q1 2022 May 16, 2022	BUY	$24.84 - $36.12 $729,302 - $1.06 Million	29,360 New	29,360 $1 Million

Others Institutions Holding SDGR

# of Institutions

235

Shares Held

60.7M

Call Options Held

726K

Put Options Held

329K

View Full List

About Schrodinger, Inc.

Ticker SDGR
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 62,028,400
Market Cap $1.23B
Description
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences i...

More about SDGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account